Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 4/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.45 |
| ▸ | NOS2 | P35228 | 3/20 | 0.43 |
| ▸ | NOS3 | P29474 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.42 |
| ▸ | GGT1 | P19440 | 2/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13828872 | 1.00 | SLC7A5 (0.50) | SLC7A5SLC1A1SLC1A3SLC1A2NOS2 | |
| SCHEMBL1233079 | 1.00 | SLC7A5 (0.50) | SLC7A5SLC1A1SLC1A3SLC1A2NOS2 | |
| SCHEMBL13828690 | 1.00 | SLC7A5 (0.50) | SLC7A5SLC1A1SLC1A3SLC1A2NOS2 | |
| SCHEMBL12900723 | 1.00 | SLC7A5 (0.50) | SLC7A5SLC1A1SLC1A3SLC1A2NOS2 | |
| SCHEMBL3813048 | 1.00 | SLC7A5 (0.50) | SLC7A5SLC1A1SLC1A3SLC1A2NOS2 | |
| SCHEMBL1233926 | 1.00 | SLC7A5 (0.50) | SLC7A5SLC1A1SLC1A3SLC1A2NOS2 | |
| SCHEMBL1233077 | 1.00 | SLC7A5 (0.50) | SLC7A5SLC1A1SLC1A3SLC1A2NOS2 | |
| SCHEMBL13828726 | 1.00 | SLC7A5 (0.50) | SLC7A5SLC1A1SLC1A3SLC1A2NOS2 | |
| SCHEMBL12900073 | 1.00 | SLC7A5 (0.50) | SLC7A5SLC1A1SLC1A3SLC1A2NOS2 | |
| SCHEMBL13828751 | 1.00 | SLC7A5 (0.50) | SLC7A5SLC1A1SLC1A3SLC1A2NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| US-11534114-B2 | 18F labeled amino acids, derivatives thereof and method of making same | SIMON FRASER UNIVERSITY (CA) | 2022-12-27 | — | — | US | disclosed |
| EP-2086924-B1 | [F-18]-LABELED L-GLUTAMIC ACID, [F-18]-LABELED L-GLUTAMINE, DERIVATIVES THEREOF AND USE THEREOF AND PROCESSES FOR THEIR PREPARATION | PIRAMAL IMAGING SA (CH) | 2018-09-12 | — | — | EP | disclosed |
| US-8747809-B2 | Single diastereomers of 4-fluoroglutamine and methods of their preparation and use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-06-10 | — | — | US | disclosed |
| US-8747809-B2 | Single diastereomers of 4-fluoroglutamine and methods of their preparation and use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-06-10 | — | — | US | disclosed |
| US-8747809-B2 | Single diastereomers of 4-fluoroglutamine and methods of their preparation and use | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-06-10 | — | — | US | disclosed |
| US-20120288444-A1 | SINGLE DIASTEREOMERS OF 4-FLUOROGLUTAMINE AND METHODS OF THEIR PREPARATION AND USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120288444-A1 | SINGLE DIASTEREOMERS OF 4-FLUOROGLUTAMINE AND METHODS OF THEIR PREPARATION AND USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-11-15 | — | — | US | disclosed |
| WO-2011020018-A1 | SINGLE DIASTEREOMERS OF 4-FLUOROGLUTAMINE AND METHODS FO THEIR PREPARATION AND USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2011-02-17 | — | — | WO | disclosed |
| EP-1923382-A1 | [18F] labelled L-glutamic acid, [18F] labelled glutamine, their derivatives, their use and processes for their preparation | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-05-21 | — | — | EP | disclosed |
| EP-1303258-B1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2006-10-11 | — | — | EP | disclosed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | disclosed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11534114-B2 | 18F labeled amino acids, derivatives thereof and method of making same | SLC1A5, BCAT2, BCAT1 | SLC7A5 14/4885SLC1A1 7/4885SLC1A3 5/4885 |
| US-20120288444-A1 | SINGLE DIASTEREOMERS OF 4-FLUOROGLUTAMINE AND METHODS OF THEIR PREPARATION AND USE | GCG, FPGS, FOLH1 | SLC7A5 106/4885SLC1A1 349/4885SLC1A3 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.